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Abstract
Background: Cigarette smoking causes about one of every five deaths in the U.S. each year. In 2013 the prevalence
of smoking in our institution’s trauma population was 26.7 %, well above the national adult average of 18.1 %
according to the CDC website. As a quality improvement project we implemented a multimodality smoking
cessation program in a high-risk trauma population.
Methods: All smokers with independent mental capacity admitted to our level I trauma center from 6/1/2014 until 3/
31/2015 were counseled by a physician on the benefits of smoking cessation. Those who wished to quit smoking were
given further counseling by a pulmonary rehabilitation nurse and offered nicotine replacement therapy (e.g. nicotine
patch). A planned 30 day or later follow-up was performed to ascertain the primary endpoint of the total number of
patients who quit smoking, with a secondary endpoint of reduction in the frequency of smoking, defined as at least a
half pack per day reduction from their pre-intervention state.
Results: During the 9 month study period, 1066 trauma patients were admitted with 241 (22.6 %) identified
as smokers. A total of 31 patients with a mean Injury Severity Score (ISS) of 14.2 (range 1–38), mean age of
47.6 (21–71) and mean years of smoking of 27.1 (2–55), wished to stop smoking. Seven of the 31 patients,
(22.5 %, 95 % confidence interval [CI] of 10–41 %) achieved self-reported smoking cessation at or beyond
30 days post discharge. An additional eight patients (25.8 %, 95 % CI 12–45 %) reported significant reduction
in smoking.
Conclusions: Trauma patients represent a high risk smoking population. The implementation of a smoking
cessation program led to a smoking cessation rate of 22.5 % and smoking reduction in 25.8 % of all identified smokers
who participated in the program. This is a relatively simple, inexpensive intervention with potentially far reaching and
beneficial long-term health implications. A larger, multi-center prospective study appears warranted.
LEVEL OF EVIDENCE: Therapeutic Study, Level V evidence.
Keywords: Trauma preventative care, Smoking, Smoking cessation
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Background
According to the World Health Organization (WHO), in
2012, 21 % of the global population smoked tobacco [1].
Annually, tobacco usage worldwide causes the direct
death of over 5 million people with an additional
600,000 people dying from second-hand smoke [2]. In
the United States alone, cigarette smoking accounts for
one of every five deaths each year [3]. As compared to
nonsmokers, the life expectancy of smokers is lowered
by 13.2 years for men and 14.5 years for women [4].
Smokers are at an increased risk for chronic obstructive
pulmonary disease (COPD) with an absolute risk (AR) of
25 % and lung cancer with an average relative risk (RR)
of 15 to 30 [5, 6]. Smoking also increases the likelihood
of developing chronic diseases, such as ischemic heart
disease (RR = 2.2), cerebrovascular disease (RR = 1.6) and
atherosclerotic cardiovascular disease (RR = 1.6) [7].
Smoking is linked to countless malignancies including
40–70 % of bladder cancers and 30 % of pancreatic
cancers [8].
Additionally, cigarette smoking poses a financial bur-
den. Assuming a pack of cigarettes costs 7 dollars, smok-
ing one pack a day will cost an individual over $2500
per year. Nationally, from 2001 to 2004, the average
financial burden of smoking was approximately $193
billion per year. Of this amount, $96 billion is attributed
to health care cost, while the remaining $97 billion is
accounted from lost productivity [9].
The Center for Disease Control (CDC) estimates that
there are over 42 million adults in the United States who
smoke cigarettes [10]. In 2010, the CDC reported that ap-
proximately 69 % of smokers were interested in quitting
and 52 % of smokers had made a quit attempt in the past
year [11]. Multimodal interventions, specifically combined
nicotine replacement therapy (NRT) and counseling have
demonstrated cessation rates from 20–33 % [12].
A national survey documented an overall decline of
cigarette smoking from 21 % in 2005 to 18 % in 2013
[10]. In 2013, only 16.6 % of adults were reported to be
smokers in the state of Massachusetts [13]. However at
our institution in 2013, the prevalence of smoking
among our trauma population was much higher at 27 %.
The American College of Surgeons (ACS) has tasked all
trauma centers with providing education on alcohol ces-
sation, as studies have shown alcohol to be linked to
traumatic injuries. Unlike this stance on alcohol, the
ACS has no mandate for smoking cessation counseling.
Prior to implementation of this program, our institution
had no formalized protocol for smoking cessation. Previ-
ous studies have demonstrated that impulsivity is related
to heightened nicotine dependence; however the exact
relationship is far more complex than a simple causal
relationship [14]. The purpose of this study was to im-
plement a multimodality smoking cessation program in
a high-risk trauma population. We hypothesized this
would lead to smoking cessation in our trauma patient
population who previously received no care to address
smoking.
Methods
After obtaining Institutional Review Board exemption,
all smokers with independent mental capacity were en-
rolled from June 1, 2014 to March 31st, 2015 at Baystate
Medical Center, a level one trauma center. Participants
received initial physician counseling regarding smoking
cessation. All physician counselors were given a docu-
ment compiled by the investigators before the start of
the intervention. This included detrimental effects of
smoking, benefits of smoking cessation, and responses
for common reasons that patients refuse to stop smoking.
If the patient desired smoking cessation, demographics
including: gender, age, injury severity score (ISS), thorax
abbreviated injury scale (AIS), and number of years smok-
ing were obtained. They also were given educational pam-
phlets regarding benefits of smoking cessation and
outpatient resources. All patients were offered nicotine
replacement therapy (NRT) via a nicotine patch.
If admitted, a pulmonary rehabilitation nurse con-
sultation with further counseling was ordered. Patients
agreed to participate in an outpatient survey at 30 days
or later. This survey assessed the primary endpoint of
smoking cessation as well as the secondary endpoint
of significant reduction in smoking defined as at least
half a pack per day.
Descriptive statistics (mean and range) for continuous
variables and percents for categorical variables were
reported for all demographic and clinical variables.
Rates of successful smoking cessation and significant
smoking reduction and their 95 % confidence intervals
were calculated.
Results
During the 9 month study period from June 1st, 2014
until March 31st, 2015, 1066 patients were admitted to
Baystate Medical Center, a level one trauma center.
Two-hundred forty one patients (22.6 %) were identified
as smokers. Only 31 patients (23 male, eight female)
wished to pursue smoking cessation. These patients had
a mean ISS of 14.2 (range 1–38) and mean thorax AIS
of 2.1 (0–5). The participants had a mean age of 47.6
(21–71) and mean years of smoking of 27.1 (2–55). A
100 % survey response was achieved at the 30 day or
later designated follow-up. All participants were outpa-
tients at this point with the capability to re-start smok-
ing if desired. Seven of the 31 patients, (22.5 %, 95 %
Confidence Interval Confidence Interval [CI] of 10–
41 %) achieved smoking cessation at the follow-up. Eight
patients (25.8 %, 95 % [CI] of 12–45 %) reported
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significant reduction in smoking, defined by at least
half a pack per day reduction (Table 1). Thirteen of the
24 patients who did not achieve smoking cessation still
desired to quit. The most common impediment to
smoking cessation of those unable to quit was with-
drawal symptoms (20.8 %). The second most common
impediment was an inability to procure nicotine replace-
ment therapy as an outpatient (16.7 %). An additional
4.1 % of remaining smokers cited alcohol influence and
lack of motivation. On univariate analysis, comparing the
subgroups of those who achieved 30 day cessation and
those who did not, three variables were statistically sig-
nificant (p < .05): LOS, ISS, and Thorax AIS (Table 2).
After controlling for ISS in multiple logistic regression,
the difference between the smoking cessation group
and non-cessation group in LOS was not statistically
significant (p = 0.19).
Discussion
Smoking is associated with harmful effects on every organ
in the body and is well recognized as the leading cause of
preventable illness and death [15]. Smoking adversely af-
fects orthopedic injuries. A recent systematic review was
performed by Scolaro et al. included 19 papers (seven pro-
spective, 12 retrospective cohort) examining the effects of
smoking on orthopedic trauma. They discovered an ad-
justed odds ratio of nonunion in smokers of 2.32 and an
approximately 6 week longer mean healing time compared
to nonsmokers. There was also a trend toward more post-
operative wound infections [16].
The link between smoking and pulmonary disease is
even more established. The pathophysiology of this
process is beyond the scope of this manuscript, but
some mechanisms include direct epithelial injury, car-
cinogen exposure, oxidative stress and mucociliary dys-
function [17]. Smoking is shown to have deleterious
effects on respiratory failure in trauma. A retrospective
review by Resnick et al. found smokers on average spent
five more days of mechanical ventilation compared to
nonsmokers [18]. Smoking is also considered one of the
main modifiable risk factors for all types of pneumonia,
including ventilator-associated pneumonia [19]. Calfee et
al found smoking to be a risk factor for acute respiratory
distress syndrome (odds ratio 2.28) in patients even with
non-pulmonary sepsis [20]. In a prospective observa-
tional study conducted by Lucidarme on mechanically
ventilated patients, there was a significant difference in
morbidity, especially agitation, self-removal of tubes and
need for sedatives and restraints when comparing smokers
versus nonsmokers [21].
Smoking has also been associated with impaired
wound healing. Smoking has deleterious effects on neu-
trophil responsiveness and migratory and bactericidal
function. Smoking also decreases mucosal and subcuta-
neous blood flow by as much as 40 % in some studies. It
additionally causes oxidative stress through creation of
reactive oxygen species [22].
In 2006, the American College of Surgeons Committee
on Trauma (COT) published their first document on
Alcohol Screening and Brief Intervention for Trauma
Patients [23]. The need for this document is obvious
given that nearly 50 % of trauma admissions have a posi-
tive blood alcohol level. In our trauma population we
found a significant rate of smoking, 22.6 %. A retrospect-
ive chart review by Ferro et al. found an even higher
smoking rate of 42.9 % in their trauma population [24].
Hence, like alcohol, this is a common problem in the
injured patient.
Smoking cessation creates immediate benefits, which
help the injured patient. Within hours of cessation, tissue
blood flow and oxygen levels return to normal. At ap-
proximately two weeks of abstinence platelet function
normalizes. Vitamin C levels and collagen synthesis ap-
pear to take approximately 4 weeks to normalize, although
some benefit is seen earlier. By 6–8 weeks mucociliary
function normalizes and perioperative complications de-
cline. The effects of nicotine replacement therapy is not
clear, a systematic review by Sorensen concluded that
there is no evidence to suggest that nicotine replacement
therapy has a detrimental or beneficial effect on postoper-
ative outcomes or wound healing [22].
In terms of our patient population, there was no differ-
ence between those who achieved cessation and those
who did not in terms of age, years of smoking, or readmis-
sion rate. There was a statistically significant difference
in Thorax AIS, ISS, and LOS. Those achieving smoking




Mean age (Range) 47.6 (21–71)
Mean ISS (Range) 14.2 (1–38)
Mean years smoking (Range) 27.1 (2–55)
Stopped smoking at 30 days (percent) 7/31 (23 %)
Significantly decreased smoking (percent) 8/31 (26 %)
Table 2 Demographic and outcomes analysis
Variable No (Mean/CI) Yes (Mean/CI) Significance
Age 46.9(41.6–52.3) 50(33.5–66.5) 0.61
Years smoked 26.3(20.7–32.0) 30(10.0–50.0) 0.58
LOS(CI) 4.3 (2.8–5.8) 7.6 (4.6–10.6) 0.0333
ISS(CI) 11.4 (7.8–15.1) 21.1 (13.5–28.8) 0.0133
Thorax AIS(CI) 1.6 (1.0–2.3) 3.6 (2.7–4.5) 0.0031
Readmit rate 8.30 % 14.30 % 0.639
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cessation had a higher thorax AIS. It makes sense that
patients with significant pulmonary injuries would be
more amenable to cessation as they can easily compre-
hend the cause and effect relationship. ISS in the smok-
ing cessation group was significantly higher however
we do not believe there is a causal relationship. Finally,
in terms of LOS being significantly higher for cessation
patients, as previously mentioned this difference was
no longer statistically significant when we controlled
for ISS. Larger studies will be required to better eluci-
date which patients to focus on for counseling and
what potential short term benefits can be achieved with
smoking cessation in trauma patients.
The long term benefits of smoking cessation are quite
profound. According to the WHO and CDC at one year
from cessation the risk of coronary artery disease is half
of a smokers and by 5 years the risk of stroke is that of a
nonsmoker [1, 2, 4].
The importance of smoking cessation is clear for all
patients, but should have the utmost significance for
those who are traumatically injured. In our study, we
achieved a smoking cessation rate of 22.5 %. The literature
contains varied success rates depending on the modalities
utilized, patient population and endpoint time, as there is
certainly a component of recidivism. A Cochrane review
of physician counseling for smoking cessation included 42
trials and found a 1–3 % improvement in cessation with
only physician counseling, however, noted a higher rate
with more intensive counseling and/or follow-up [25]. A
recent randomized trial by Halpern et al. found a 30 day
abstinence rate ranging from 10.5 to 22.6 % using financial
incentives [26]. Other studies that utilize a multimodality
approach, including behavioral therapy, counseling, nico-
tine replacement and pharmacologic therapy, have re-
ported success rates ranging from 15–68 % [11, 12, 27].
Eisenberg et al. performed a meta-analysis, which included
only randomized controlled trials, found an abstinence
rate of 16.4 % for nicotine replacement therapy alone,
30.3 % for pharmacologic therapy alone and 35.5 % for
combination therapy [28]. Other studies that include nico-
tine replacement therapy plus behavioral counseling have
found abstinence rates ranging from 20–33 % depending
on the intensity of counseling [12].
When assessing our financial and fixed resources, our
smoking cessation program would need to be easy to
implement and cost effective. Thus, the upfront cost of
financial incentives was deemed prohibitive. In terms of
pharmacologic therapy there are 2 FDA approved op-
tions, Varenicline (Chantix) and Buproprion (Zyban).
Buproprion therapy is associated with an alarmingly high
rate of insomnia (30–50 %), dry mouth (11 %) and other
less common side effects such as tremor (3.4 %), rash
(2.4 %), and seizures (0.1 %) [29]. Varenicline has two
major safety concerns, namely neuropsychiatric and
cardiovascular. The latter led to an FDA advisory in 2011
that there may be increased risk of cardiovascular events
in patients with known cardiovascular disease. Other
commonly reported side effects include insomnia, nausea,
visual disturbances, syncope and moderate to severe skin
reactions. Given the relative frequency of adverse medica-
tion reactions, we felt it prudent to only use nicotine re-
placement therapy despite a slightly inferior cessation rate.
In the future, we realize that engagement of our primary
care physicians to assist with the prescription and main-
tenance of these medications may be helpful as the most
common impediment to quitting was withdrawal symp-
toms, which may be ameliorated via these medications.
Furthermore, U.S. insurance plans are required to
cover tobacco-cessation interventions including behav-
ioral counseling and medications approved by the Food
and Drug Administration. This may alleviate our second
most common cited impediment to quitting, which was
an inability to procure nicotine replacement therapy.
In addition to our rate of cessation we also achieved a
25.8 % reduction in smoking, which we defined by half a
pack per day. Multiple studies have shown that even in
those not interested in quitting, a reduction in smoking
leads to a higher future rate of smoking cessation [30].
Some of the limitations to our study include lack of
power, non-randomization, and length of follow-up. In
terms of sample size, this was originally designed as a
quality improvement project that achieved good results,
we hope to continue this process of accrual and poten-
tially expand it to our emergency general surgery patients
as well. Since this is not a randomized controlled-blinded
trial there are inherent biases such as selection bias as we
did not control for potential confounders, including recent
attempts to quit, concurrent substance abuse or other fac-
tors that may be unrecognized impediments. Additionally,
with any interview there is a potential for interviewer bias;
an attempt to minimize this was achieved by using a stan-
dardized script questionnaire. Finally, there is certainly a
known potential for response bias, namely false positives
for smoking cessation. Although in the setting of a non-
financial gain scenario (i.e. no financial incentive for
quitting), this is minimized as much as possible short of
confirmatory nicotine testing.
Conclusion
Smoking has significant financial and health ramifications
for trauma patients and healthcare as a whole. The imple-
mentation of a smoking cessation program led to a smoking
cessation rate of 22.5 % and smoking reduction in 25.8 % of
all identified smokers who participated in the program. This
is a relatively simple and inexpensive intervention with
potentially far reaching and beneficial long-term health im-
plications. A multicenter evaluation including trauma and
potentially emergency general surgical patients is warranted.
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